INDUSTRY

Improving Health Global Patient Meeting – TEVA

Improving Health, Global Patient Advocacy Dialogue meeting; Monday 25th and Tuesday 26th September at the Teva office in Amsterdam. The meeting will be hosted at Teva’s Amsterdam office which is located at Piet Heinkade 107, 1019 GM Amsterdam, The Netherlands Draft Agenda Monday 25th September 2017 10.00 – 12noon Welcome, Introductions Recap from March Mtg, Washington DC 12noon – 1pm Lunch 1.00 – 3.30pm Patient Policy: What …

Improving Health Global Patient Meeting – TEVA Read More »

Novartis announces AMG 334 significantly reduces patients’ monthly migraine days in phase II study of chronic migraine prevention

Phase II 20120295 study of AMG 334 met primary endpoint, confirming efficacy and safety in patients with chronic migraine over 12 weeks of treatment Migraine is a leading cause of disability, affecting more than 10% of people worldwide – within the overall migraine population, people with chronic migraine experience the greatest impact on daily activities …

Novartis announces AMG 334 significantly reduces patients’ monthly migraine days in phase II study of chronic migraine prevention Read More »

Positive Phase III data for migraine drug Fremanezumab

Positive results from a Phase III HALO study of fremanezumab, an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody investigational treatment for the prevention of migraine, have been announced by Israel-based Teva Pharmaceutical Industries (NYSE: TEVA). In the chronic migraine (CM) study, patients treated with fremanezumab experienced statistically-significant reduction in the number of monthly headache days of …

Positive Phase III data for migraine drug Fremanezumab Read More »

The results of greater occipital nerve block applied for migraine headache

OBJECTIVES: The aim of this study was to evaluate the efficacy of greater occipital nerve (GON) block in the treatment of migraine patients. METHODS: This study included 28 patients diagnosed with migraine between 2014 and 2015. The GON block procedure was applied by administering 1.5 ml of 2% lidocaine 2 cm lateral and 2 cm …

The results of greater occipital nerve block applied for migraine headache Read More »

Disability & Catastrophizing In Chronic Migraine vs Temporomandibular Disorder

Patients with chronic migraine share features with individuals with temporomandibular disorders that include kinesiophobia and neck disability, according to a cross-sectional study recently published in Pain Medicine.1 A growing body of research indicates a number of shared features between chronic migraine and TMD. For example, patients with chronic migraine, but not headache-free individuals, commonly experience …

Disability & Catastrophizing In Chronic Migraine vs Temporomandibular Disorder Read More »

Scroll to Top